United StatesThe U.S. Centers for Medicare and Medicaid Services (CMS) has finalized a rule that removes special payment pathways for medical devices labeled as 'breakthrough' by the Food and Drug Administration (FDA). These pathways previously allowed such devices to receive supplemental Medicare payments without needing to prove they offered significant clinical improvements over existing technologies. Starting in fiscal year 2028, breakthrough devices will need to demonstrate substantial clinical benefits before qualifying for these payments. The change aims to ensure that Medicare funds are used to support technologies that have been proven to improve patient outcomes compared to current treatments. This shift could affect how hospitals adopt new medical technologies and how device manufacturers seek reimbursement.
Bias read (Center): The article presents a factual update on a regulatory change by CMS regarding Medicare payments for medical devices. It does not exhibit overtly biased language, one-sided sourcing, or omission of context. The framing remains neutral, focusing on the procedural and policy aspects of the change.
